Elanco Animal Health Incorporated (ELAN) P/E Ratio History
Deep ValueTrading at -51.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2025
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Elanco Animal Health Incorporated (ELAN) trades at a price-to-earnings ratio of -51.5x, with a stock price of $24.22 and trailing twelve-month earnings per share of $-0.48.
The current P/E is 144% below its 5-year average of 116.9x. Over the past five years, ELAN's P/E has ranged from a low of 14.1x to a high of 305.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ELAN trades at a 333% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ELAN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ELAN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ELAN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ELAN P/E vs Peers
Animal health pharmaceuticals and vaccines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $33B | 13.1Lowest | 1.09 | +10% | |
| $878M | 139.6 | - | +107% | |
| $1B | 26.8 | 3.58 | +1883%Best | |
| $8B | 35.0 | - | -43% | |
| $2B | 23.9 | - | +419% | |
| $1.0T | 47.8 | 1.66 | +96% | |
| $143B | 18.5 | - | -4% | |
| $281B | 15.6 | 0.74Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ELAN Historical P/E Data (2018–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $20.14 | $0.07 | 305.2x | +161% |
| FY2025 Q2 | Jun 30 2025 | $14.28 | $0.87 | 16.5x | -86% |
| FY2025 Q1 | Mar 31 2025 | $10.50 | $0.74 | 14.1x | -88% |
| FY2024 Q4 | - | $12.11 | $0.68 | 17.9x | -85% |
| FY2024 Q3 | Sep 30 2024 | $14.69 | $0.40 | 36.3x | -69% |
| FY2019 Q4 | - | $29.45 | $0.19 | 153.8x | +32% |
| FY2019 Q3 | Sep 30 2019 | $26.59 | $0.26 | 103.5x | -11% |
| FY2019 Q2 | Jun 30 2019 | $33.80 | $0.39 | 86.7x | -26% |
| FY2019 Q1 | Mar 31 2019 | $32.07 | $0.11 | 291.5x | +149% |
| FY2018 Q4 | Dec 31 2018 | $31.53 | $0.22 | 143.3x | +23% |
Average P/E for displayed period: 116.9x
Full Stock Analysis
Deep dive into ELAN consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ELAN — Frequently Asked Questions
Quick answers to the most common questions about buying ELAN stock.
What is ELAN's P/E ratio?
Elanco Animal Health Incorporated (ELAN) trailing twelve-month P/E ratio is -51.5x, based on TTM diluted EPS of $-0.48. The 5-year average P/E is 116.9x and the historical range spans 14.1x to 305.2x.
Is ELAN stock overvalued or undervalued?
ELAN trades at -51.5x P/E, below its 5-year average of 116.9x. At the 0th percentile of its historical range (14.1x–305.2x), the stock is priced at a discount to its own history.
Is ELAN stock expensive?
No, ELAN is not expensive on a historical basis. The current P/E of -51.5x is below the 5-year average of 116.9x and sits at the 0th percentile of its valuation range.
What is ELAN's historical P/E range?
Over the past 5 years, ELAN's P/E ratio has ranged from 14.1x to 305.2x, with a median of 103.5x and an average of 116.9x. The current P/E of -51.5x places the stock at the 0th percentile of this range. Full historical data spans 2018–2025.
How does ELAN's P/E compare to the S&P 500?
ELAN trades at -51.5x P/E versus the S&P 500 median of 24.4x. The 311% discount to the market suggests lower growth expectations or perceived higher risk.
How does ELAN's valuation compare to Healthcare peers?
Elanco Animal Health Incorporated P/E of -51.5x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ELAN's PEG ratio?
ELAN PEG ratio is N/A, based on a P/E of -51.5x and EPS growth of -169.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ELAN's earnings yield?
ELAN earnings yield is N/A, the inverse of its -51.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.